Curated News
By: NewsRamp Editorial Staff
September 19, 2025
Nutriband Secures FDA Meeting for Abuse-Deterrent Fentanyl Patch Technology
TLDR
- Nutriband's FDA approval for AVERSA Fentanyl technology provides a competitive edge in addressing unmet medical needs through novel abuse-deterrent transdermal patches.
- The FDA Type C Meeting on September 18 focuses on Nutriband's CMC plans for AVERSA Fentanyl development using the 505(b)(2) regulatory pathway.
- Nutriband's abuse-deterrent fentanyl patch technology enhances patient safety by preventing misuse and accidental exposure to potent medications.
- Nutriband's AVERSA technology transforms transdermal patches into abuse-resistant systems leveraging existing drug safety data for faster regulatory approval.
Impact - Why it Matters
This development matters because it addresses the critical opioid crisis by introducing technology that could significantly reduce fentanyl abuse and accidental exposures. Fentanyl is responsible for the majority of opioid overdose deaths, and an abuse-deterrent patch could save countless lives while allowing legitimate pain patients to access necessary medication safely. The FDA's engagement signals recognition of the technology's potential impact on public health, potentially leading to faster regulatory approval and widespread adoption in medical practice.
Summary
Nutriband Inc. (NASDAQ: NTRB), a transdermal pharmaceutical developer, has achieved a significant regulatory milestone with FDA engagement for its AVERSA™ abuse-deterrent fentanyl patch technology. The company secured approval for a Type C Meeting scheduled for September 18 with the FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine, focusing on Chemistry, Manufacturing, and Controls (CMC) plans that span the entire development and commercialization timeline. This crucial FDA recognition addresses the complete development arc from Investigational New Drug (IND) submission through 505(b)(2) New Drug Application (NDA) approval, leveraging existing fentanyl safety data while focusing regulatory review on the novel abuse-deterrent components.
The AVERSA™ technology represents Nutriband's lead product under development, designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This innovative technology can be incorporated into any transdermal patch, positioning Nutriband at the forefront of addressing critical unmet medical needs in pain management and opioid safety. The company's progress is being highlighted through MissionIR, part of the Dynamic Brand Portfolio at IBN, which provides comprehensive investor relations and communications services to enhance visibility within the investment community. For more detailed information, readers can visit the InvestorBrandNetwork or access the full article through the provided links.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Secures FDA Meeting for Abuse-Deterrent Fentanyl Patch Technology
